Solid Biosciences (SLDB) Competitors

Solid Biosciences (NASDAQ:SLDB) and Schrodinger (NASDAQ:SDGR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Is SLDB or SDGR more profitable?

Solid Biosciences has a net margin of 0.00% compared to Schrodinger's net margin of -83.39%. Schrodinger's return on equity of -44.74% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-68.15%	-55.33%
Schrodinger	-83.39%	-44.74%	-26.29%

Do analysts rate SLDB or SDGR?

Solid Biosciences currently has a consensus price target of $15.10, indicating a potential upside of 180.15%. Schrodinger has a consensus price target of $32.75, indicating a potential upside of 60.78%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Solid Biosciences is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.17
Schrodinger	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Which has more risk & volatility, SLDB or SDGR?

Solid Biosciences has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Does the media favor SLDB or SDGR?

In the previous week, Solid Biosciences had 1 more articles in the media than Schrodinger. MarketBeat recorded 8 mentions for Solid Biosciences and 7 mentions for Schrodinger. Solid Biosciences' average media sentiment score of 0.72 beat Schrodinger's score of 0.31 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings & valuation, SLDB or SDGR?

Solid Biosciences has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$124.70M	-$2.99	-1.80
Schrodinger	$207.54M	7.20	-$187.12M	-$2.63	-7.75

Do insiders & institutionals have more ownership in SLDB or SDGR?

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 79.1% of Schrodinger shares are held by institutional investors. 13.6% of Solid Biosciences shares are held by company insiders. Comparatively, 8.6% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Solid Biosciences beats Schrodinger on 12 of the 16 factors compared between the two stocks.